Additive Anti-inflammatory Action for Aortopathy & Arteriopathy

Clinical Outcome of Aortic Disease in the Chinese Patients

Aortic disease refers to the blood in the aortic lumen entering the aortic mediastinum from the tear of the aortic intima, separating the mediastinum and extending along the long axis of the aorta to form the true and false separation state of the aortic wall. This disease is rare, and the incidence rate is 100 thousand to 200 thousand a year, with the peak age of 50-70 years old. 65%-70% patients died in the acute stage due to cardiac congestion and arrhythmia, so early diagnosis and treatment is very necessary. The aim of this study is analyze clinical outcome of Chinese patients with acute aortic syndrome and aortic aneurysm.

Study Overview

• Status: Enrolling by invitation
• Conditions: Aortic Aneurysm; Aortic Dissection
• Intervention / Treatment: Other: observation

Detailed Description

Aortic disease refers to the blood in the aortic lumen entering the aortic mediastinum from the tear of the aortic intima, separating the mediastinum and extending along the long axis of the aorta to form the true and false separation state of the aortic wall. Risk factors for aortic dissection included hypertension, cystic necrosis or degeneration of the middle aorta, hereditary connective tissue disease, congenital two-lobe active pulse valve, arteritis, aneurysm, atherosclerosis and iatrogenic injury, etc. The leading cause of aortic dissection is hypertension, and more than 75% of aortic dissection is associated with hypertension.Therefore, for hypertension patients to do a good job in the prevention and control of hypertension, pay attention to the regular use of antihypertensive drugs and monitoring blood pressure. In case of sudden chest and back lacerations, the patient should be immobilized in bed, contacted with an ambulance and sent to the hospital for emergency treatment, so as to avoid greater risks. The aim of this study is analyze clinical outcome of Chinese patients with acute aortic syndrome and aortic aneurysm.

• Study Type: Observational
• Enrollment (Estimated): 10000

Contacts and Locations

Study Locations

• China
  • Beijing, China
    • Beijing Chaoyang Hospital
  • Beijing, China
    • Beijing Anzhen Hospital
  • Bengbu, China
    • The First Affiliated Hospital of Bengbu Medical College
  • Changsha, China
    • Xiangya Hospital Central South University
  • Guangzhou, China
    • Guangzhou Medical University
  • Guilin, China
    • the First Affiliated Hospital of Guilin Medical College
  • Nanjing, China, 210029
    • The First Affiliated Hospital of Nanjing Medical University
  • Nanjing, China
    • Nanjing First Hospital, Nanjing Medical University
  • Qingdao, China
    • The Affiliated Hospital of Qingdao University
  • Shanghai, China
    • Shanghai East Hospital
  • Shantou, China
    • The First Affiliated Hospital of Shantou University Medical College
  • Tianjin, China
    • Tianjin Chest Hospital
  • Tianjin, China
    • TEDA International Cardiovascular Hospital
  • Xiamen, China
    • Xiamen Cardiovascular Hospital
  • Guangxi
    • Nanning, Guangxi, China
      • The First Affiliated Hospital of Guangxi Medical University
  • Heilongjiang
    • Harbin, Heilongjiang, China
      • The Second Affiliated Hospital of Harbin Medical University
  • Jiangsu
    • Yangzhou, Jiangsu, China, 225001
      • Subei People's Hospital of Jiangsu province
  • Jiangxi
    • Nanchang, Jiangxi, China, 300088
      • The Second Affiliated Hospital of Nanchang University
  • Shandong
    • Jinan, Shandong, China, 250012
      • Qilu Hospital of Shandong University
  • Shanghai
    • Shanghai, Shanghai, China
      • Shanghai DeltaHealth Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Chinese patients suffering dilated aortic disease

Description

Inclusion Criteria:

• aortic dissection
• Aortic aneurysm

Exclusion Criteria:

• No treatment was received;
• Died in the emergency room before surgery;
• Unwillingness to cooperation with study procedures or follow-up visits

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Operative mortality	Operative mortality was defined as any death, regardless of cause, occurring whether within 30 days after surgery in or out of the hospital or after 30 days during the same hospitalization subsequent to the operation.	30 days after treatment

Collaborators and Investigators

• Sponsor: Nanjing Medical University
• Collaborators: Beijing Anzhen Hospital
• Investigators: Study Director: Hong-jia Zhang, MD, Beijing Anzhen Hospital; Principal Investigator: Si-chong Qian, Beijing Anzhen Hospital; Principal Investigator: Hong Liu, Nanjing Medical University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2016
• Primary Completion (Estimated): December 31, 2025
• Study Completion (Estimated): December 31, 2025

Study Registration Dates

• First Submitted: May 19, 2020
• First Submitted That Met QC Criteria: May 19, 2020
• First Posted (Actual): May 22, 2020

Study Record Updates

• Last Update Posted (Actual): October 19, 2023
• Last Update Submitted That Met QC Criteria: October 18, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Aortic Diseases; Dissection, Blood Vessel; Acute Aortic Syndrome; Aneurysm; Aortic Aneurysm; Aortic Dissection
• Other Study ID Numbers: 5A-Plan

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No